By Lucinda Creighton, CEO & Robert O’Reilly, Strategic Counsel | Vulcan Consulting  Situation Analysis Today’s vote presents yet another “crunch moment” in the long running Brexit saga.  For those who have not been following in any great detail, this is Prime Minister Theresa May’s big moment in the House of Commons, when she will attempt to get the deal she has agreed with the European Union through by way of parliamentary vote.  This so called ‘Exit Deal’ does not set out the...

Read more

VULCAN VIEW - KEY EVENTS THIS WEEK: European Union: The Polish and Italian Election Coalition    With the European Elections in full swing, the leaders of the most popular populist parties in Poland and Italy will meet Wednesday to discuss a common strategy for the Elections in May.  Matteo Salvini and Jarosław Kaczyński (PiS) are hoping that the common ground they have concerning migration and their euroskepticism, will enable a joint position in the next election. However, they have very different views on Russia.   PiS,...

Read more

By Evelyn Schulz & Susann Jahn | Noerr  Following our article “Brexit with or without a deal: Consequences for pharmaceutical companies”, which provided a general overview of the challenges facing pharmaceutical companies, this article deals specifically with the impact of Brexit on medicinal product marketing authorisations. Whether there will be a Brexit with or without a deal is of secondary importance with regard to medicinal product marketing authorisations – this question primarily determines the period within which pharmaceutical companies will be confronted with the...

Read more